{'fraction_non_alphanumeric': 0.02833530106257379, 'fraction_numerical': 0.023612750885478158, 'mean_word_length': 5.281481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection.

THERE is considerable mortality and morbidity in the United States from perinatal group B streptococcal disease.1 , 2 Approximately 3 neonates per 1000 live births, or an estimated 11,000 infants annually, have invasive group B streptococcal disease; two thirds of these infections are caused by the Type III capsular serotype.3 Pregnancy-related morbidity (e.g., urinary tract infection, chorioamnionitis, postpartum endometritis and bacteremia, and wound infections complicating cesarean section) affects approximately 50,000 women each year.2 , 3 One method proposed for the prevention of group B streptococcal disease in mothers and their infants is active immunization of women. This proposal is based on the observation that . . .